linjc16/ctgov huggingface dataset:
Demonstration of the SPECT/CT System With CZT Detectors Imaging Performance in a Clinical Setting

Study Overview
=================
Brief Summary
-----------------
The primary purpose of the study is to obtain sample clinical images that are evaluated by physicians in support of regulatory submissions. Additionally, the study will provide data for current and future product development and it will provide clinical images and data for marketing use.

Official Title
-----------------
Demonstration of the SPECT/CT System With CZT Detectors Imaging Performance in a Clinical Setting

Conditions
-----------------
Cancer

Intervention / Treatment
-----------------
* Device: Discovery NM/CT 670 CZT Imaging Scan


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: are 18-years old and older; is able to sign and date the informed consent form; AND have been prescribed by a physician a nuclear medicine exam that is within the intended use of the device. Exclusion Criteria: Patients who were referred for dynamic nuclear medicine scan because of the need to be injected twice (once for the conventional acquisition and once for the investigational device) that would result in an increase dose burden on patient. Pregnant or lactating women Who were previously enrolled in this study; Who have contraindication for the radiopharmaceutical Who have any conditions that, in the opinion of the Investigator, would interfere with the evaluation of the results or constitute a health hazard for the subject;

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Subjects indicated for dynamic nuclear medicine scanning<br>The trial will consist of a single arm composed of subjects with preexisting indications for dynamic nuclear medicine scanning at the site. All patients will undergo nuclear medicine scintigraphy using the GE Discovery 670 NM/CT device with and without CZT enabled during a single visit. | Device: Discovery NM/CT 670 CZT Imaging Scan<br>* At a single visit, subjects will undergo nuclear medicine scintigraphy imaging scanning on the investigational GE Discovery 670 NM/CT CZT (with CZT) device and the commercial GE Discovery 670c (without CZT).<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Diagnostic Image Quality | Diagnostic Image Quality will be rated by 2 radiologist using a 5 point Likert Scale | 12 weeks | 
| Image Resolution | Image Resolution will be rated by 2 radiologist using a 5 point Likert Scale | 12 weeks |
Cancer and Literacy in Health

Study Overview
=================
Brief Summary
-----------------
Validation in French of a psychometric tool for measuring health literacy in the field of cancer

Detailed Description
-----------------
Single-centre, non-interventional questionnaire study

Official Title
-----------------
Validation in French of a Psychometric Tool for Measuring Health Literacy in the Field of Cancer

Conditions
-----------------
Cancer

Intervention / Treatment
-----------------
* Other: Questionnaire


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient aged 18 years or older, having been informed of the research Followed or having been followed at the Hôpital privé des Peupliers for a cancer Exclusion Criteria: Patient who has indicated his/her opposition to the use of his/her medical data Patient under legal protection, guardianship or curatorship

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Questionnaire|Questionnaire|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Validation of a questionnaire | Development of the questionnaire: translation of the English version, testing of the French version in group work and then back-translation. | 6 months |
Tinnitus and Arterial Hypertension

Study Overview
=================
Brief Summary
-----------------
Many authors link tinnitus to arterial hypertension. The aim of this study is to establish a possible relationship between them, analyze the severity of tinnitus related to arterial hypertension and analyze a possible influence of ototoxic drugs used to treat arterial hypertension

Detailed Description
-----------------
Arterial hypertension has been cited as a possible tinnitus etiology. Vascular abnormalities associated with it may account for cochlear and central nervous system. However, a relationship between tinnitus and arterial hypertension has never been established. The aim of this study is to analyze this relationship, comparing groups with and without arterial hypertension and the incidence of tinnitus amongst them. Inclusion and exclusion criteria try to isolate arterial hypertension as the main etiological factor, as much as possible. Presbycusis, noise exposure, metabolical diseases and genetic factors will be ruled out. A comparison will be performed inside the arterial hypertension group between subgroups that use or not ototoxic medications, such as furosemide and beta-blockers

Official Title
-----------------
Tinnitus and Arterial Hypertension.is There Any Relationship?

Conditions
-----------------
Tinnitus, Hearing Loss, Arterial Hypertension

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age between 40 and 50 arterial hypertension for group 1 at least 5 years standing arterial hypertension Exclusion Criteria: chronic noise exposure metabolic diseases family antecedents of hearing loss (except for presbycusis) pregnant women use of ototoxic drugs (except for anti-hypertensives)

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 49 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Control<br>Normal subjects | |
| AH<br>Arterial hypertension patients | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of tinnitus - have tinnitus x don't have tinnitus | The purpose of this study is to compare tinnitus incidence between patients with and without arterial hypertension. | Up to 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Severity of tinnitus - Tinnitus Handicap Inventory | Severity of tinnitus measured by Tinnitus Handicap Inventory, to evaluate differences between patients with and without arterial hypertension | Up to 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
tinnitus, hearing loss, arterial hypertension, ototoxicity
Treatment of Enuresis Nocturna by Circular Muscle Exercise (Paula Method)

Study Overview
=================
Brief Summary
-----------------
Several treatment modalities for children suffering from monosymptomathic nocturnal enuresis are available including drugs, alarms, acupuncture, pelvic floor training and biofeedback. The aim of this study is to to test if Paula Method (circular muscle exercise) can be an another treatment modality.

Detailed Description
-----------------
Paula method is based on circular muscle exercises. The theory behind the Paula method is that all sphincters in the human body work simultaneosly, mutually affecting one another possibly mediated by oscillation of the spinal cord. According to this theory, exercising the ring muscles in a certain area of the body will result in strengthening the circular muscles in other areas. This method was found to to be efficacious for treatment of urinary stress incontinence in women.

Official Title
-----------------
Treatment of Enuresis Nocturna by Circular Muscle Exercise (Paula Method)

Conditions
-----------------
Monosymptomatic Enuresis Nocturna

Intervention / Treatment
-----------------
* Drug: Desmopresin
* Behavioral: Paula Method of Circular Muscle Exercise


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age- 7 to 15 years old suffering from monosymptomatic enuresis nocturna informed consent Exclusion Criteria: UTI neurological diseases or syndromes metabolic disesaes congenital disease or malformation of the urinary tract

Ages Eligible for Study
-----------------
Minimum Age: 5 Years
Maximum Age: 15 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Desmopresin|nan|
|Behavioral: Paula Method of Circular Muscle Exercise|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Enuresis Nocturna, Paula Method, Circular muscle exercise, Sphincter
Use of Biopsy Punch for Skin Biopsies for Fibroblasts Culturing

Study Overview
=================
Brief Summary
-----------------
Fibroblasts can be cultured from human skin biopsies using fetal bovine serum and artificial growth medium. Fibroblasts cultured in this way retain the genetic characteristics of their donor but can be used for experiments where study conditions are much more precisely controlled than they can be in in vivo studies. We plan to culture fibroblasts from Pima Indians for two purposes. Firstly, to look for an in vitro system to measure insulin resistance, the underlying abnormality in Pima diabetics. Secondly, to look for biochemical markers of diabetes or obesity in Pimas employing two dimensional electrophoresis techniques.

Detailed Description
-----------------
Fibroblasts can be cultured from human skin biopsies using fetal bovine serum and artificial growth medium. Fibroblasts cultured in this way retain the genetic characteristics of their donor but can be used for experiments where study conditions are much more precisely controlled than they can be in in vivo studies. We plan to culture fibroblasts from Pima Indians for two purposes: 1) to look for an in vitro system to measure insulin resistance, the underlying abnormality in Pima diabetics; and 2) to look for biochemical markers of diabetes or obesity in Pimas employing two-dimensional electrophoresis techniques.

Official Title
-----------------
Use of Biopsy Punch for Skin Biopsies for Fibroblasts Culturing

Conditions
-----------------
Fibroblasts

Participation Criteria
=================
Eligibility Criteria
-----------------
INCLUSION CRITERIA: We will include Pima Indians who do not meet any of the exclusion criteria. EXCLUSION CRITERIA: We will exclude any seriously ill individuals, any known to have a bleeding diathesis or to be immunosuppressed or subjects who are carriers of HIV or HBV. Children will be excluded, as the age range for this study's participants is 18-50. Pregnant women will be excluded on the basis of a urinary pregnancy test. All other subjects are potentially included.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Skin Biopsy
Direct Oral Anticoagulant Management for Cardiac Device Implantation

Study Overview
=================
Brief Summary
-----------------
Each year, tens of thousands of cardiac rhythm devices including pacemaker (PM) or implantable cardioverter-defibrillator (ICD) are implanted in France. More than 25% of patients undergoing cardiac device implantation receive long-term anticoagulation therapy, that increases the incidence of pocket hematoma with potential serious consequences for patients. Although more and more patients receive direct oral anticoagulants (DOACs), limited data currently exist on the perioperative management of DOAC-treated patients undergoing cardiac device implantation and the optimal strategy remains unclear. Especially, the time of DOAC resumption after the procedure is controversial. We hypothesize that the time of DOAC resumption is the main risk factor of bleeding event in DOAC-treated patients undergoing cardiac device implantation, that is to say that a delayed DOAC resumption > 48 hours following the procedure will reduce pocket hematoma incidence compared with an early resumption, ≤ 48 hours, without increasing thromboembolic events. We propose here an observational multicentre national study to find out the optimal strategy.

Official Title
-----------------
Influence of Peri-procedural Management of Direct Oral Anticoagulants on the Incidence of Pocket Hematoma in Patients Undergoing Cardiac Rhythm Device Implantation

Conditions
-----------------
Anticoagulant, Perioperative

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: receiving DOAC (apixaban, rivaroxaban, dabigatran) for stroke prevention in atrial fibrillation at least 5 days prior to enrolment undergoing a cardiac rhythm device implantation (implantation or replacement of PM (1 or 2 leads) and ICD (1or 2 leads) with or without cardiac-resynchronization therapy informed

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| number of patients with clinically significant pocket hematoma | hematoma requiring reoperation, and/or resulting in prolongation of hospitalization, and/or requiring interruption of all anticoagulation. | 30 +/- 5 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| number of patients with thromboembolic event | transient ischemic attack, stroke, peripheral embolus, venous thromboembolism | 30 +/- 5 days |
Single Blinded First CMC Osteoarthritis Treatment

Study Overview
=================
Brief Summary
-----------------
Single blinded PRP vs. Corticosteroid vs. Placebo (normal saline) intra-articular injection for basal joint arthritis.

Official Title
-----------------
Randomized Single Blinded First CMC Osteoarthritis Treatment: Therapy and Bracing Alone vs. Intra-Articular Corticosteroid Injection vs Intra-Articular Leukocyte Depleted Platelet Rich Plasma

Conditions
-----------------
Osteoarthritis Thumb

Intervention / Treatment
-----------------
* Drug: Platelet Concentrate
* Drug: Corticosteroid injection
* Other: Normal Saline


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Stage 1-3 osteoarthritis of the basal joint Exclusion Criteria: Patients with Stage 4 1st carpometacarpal joint arthritis as described by Eaton Patients who have received a corticosteroid injection in the last year to the 1st CMC joint on the proposed study side Patients who have scaphotriquetral, radioscaphoid, or scaphotrapezial osteoarthritis Patients who have concurrent DeQuervain's tenosynovitis or intersection syndrome or have been treated for either of these in the last 3 months Patients undergoing evaluation of cervical radiculopathy Patients with fibromyalgia or inflammatory rheumatic disease Patients with Pressier disease, Kienbock's, or avascular necrosis of the scaphoid Patients with any history of primary or secondary bone tumor Patients that are pregnant or terminally ill

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: PRP<br>Intra-articular injection of platelet rich plasma. | Drug: Platelet Concentrate<br>* Platelet Rich plasma<br>|
| Active Comparator: Corticosteroid<br>Intra-articular injection of kenalog. | Drug: Corticosteroid injection<br>* Kenalog<br>|
| Placebo Comparator: Normal Saline<br>Intra-articular injection of normal saline | Other: Normal Saline<br>* Control Group - Placebo<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Disabilities arm shoulder and hand score | functional score | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pinch Strength | Objective measurement | 1 year |
Apple Women's Health Study

Study Overview
=================
Brief Summary
-----------------
This is an observational longitudinal study to advance the understanding of menstrual cycle and gynecologic health conditions including PCOS, infertility and breast cancer.The study will be hosted within the Research app(available on App Store), which allows a user to find, enroll, and participate in Apple-supported health-related research studies.

Official Title
-----------------
Apple Women's Health Study

Conditions
-----------------
Infertility, Menstrual Cycle, Ovulation, Menstruation, Polycystic Ovary Syndrome, Menopause, Reproduction, Reproductive Health

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Have menstruated at least once Be at least 18 years old (at least 19 years old in Alabama and Nebraska, at least 21 years old in Puerto Rico) Live in the United States of America Be comfortable communicating in written and spoken English Have installed the Apple Research app on your iPhone Not share your iCloud account or iPhone with anyone else Be willing and able to provide informed consent to participate in the study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Identify Menstrual Cycle Patterns | Characterized using duration of menstrual flow, and cycle length in unit of days. | Up to 10 years | 
| Epidemiologic Description of Menstrual Cycle | Characterized using cycle patterns and self-reported demographics, no unit of measure | Up to 10 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Determine prevalence of gynecologic health conditions | Characterized using menstrual cycle patterns and self-reported health conditions, no unit of measure | Up to 10 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Menstruation, Menstrual Cycle, Ovulation, Polycystic Ovary Syndrome, Infertility, Menopause, Reproduction, Reproductive Health
A Pilot Study to Explore the Role of Gut Flora in Epidermolysis Bullosa

Study Overview
=================
Brief Summary
-----------------
This study seeks to correlate microbiome sequencing data with information provided by patients and their medical records.

Detailed Description
-----------------
The goal of this Research Study is to better understand how the genetic information in subject's microbiome correlates to Epidermolysis Bullosa

Official Title
-----------------
A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Epidermolysis Bullosa

Conditions
-----------------
Epidermolysis Bullosa, Epidermolysis Bullosa Simplex, Epidermolysis Bullosa Dystrophica

Intervention / Treatment
-----------------
* Other: No intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Signed informed consent, demonstrating that the patient understands the procedures required for the study and the purpose of the study i. May be signed by parent or legal guardian in the case of minor or adult unable to provide consent Male or female of all ages. (interest is given to children who present with autism or Crohn's and whose parents wish to analyze their children's gut flora. Also of interest analysis of development of the child's microbiome. In the case of autism, the younger the child, the better to correct the neurological problems if an association is found between autism and the microbiome) Diagnosis of Epidermolysis by at least one of the following i. Biopsy ii. Genetic testing Exclusion Criteria: Refusal to sign informed consent form History of bariatric surgery, total colectomy with ileorectal anastomosis or proctocolectomy. Postoperative stoma, ostomy, or ileoanal pouch Participation in any experimental drug protocol within the past 12 weeks Treatment with total parenteral nutrition
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients with Epidermolysis Bullosa<br>Patients who have been diagnosed with Epidermolysis Bullosa | Other: No intervention<br>* There is no intervention for this study<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correlation of Microbiome to Disease via Relative Abundance Found in Microbiome Sequencing | Relative abundance of bacterial classes within taxonomic phyla and, more broadly, within their domain will be analyzed by sequencing the gut microbiome. These data will then be categorized with Epidermolysis Bullosa | Three years |